Lode, H.N.; Holko, P.; Wieczorek, A.; Siebert, N.; Valteau-Couanet, D.; Garaventa, A.; Cañete, A.; Anderson, J.; Yaniv, I.; Ash, S.;
et al. Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison. Cancers 2025, 17, 2723.
https://doi.org/10.3390/cancers17172723
AMA Style
Lode HN, Holko P, Wieczorek A, Siebert N, Valteau-Couanet D, Garaventa A, Cañete A, Anderson J, Yaniv I, Ash S,
et al. Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison. Cancers. 2025; 17(17):2723.
https://doi.org/10.3390/cancers17172723
Chicago/Turabian Style
Lode, Holger N., Przemysław Holko, Aleksandra Wieczorek, Nikolai Siebert, Dominique Valteau-Couanet, Alberto Garaventa, Adela Cañete, John Anderson, Isaac Yaniv, Shifra Ash,
and et al. 2025. "Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison" Cancers 17, no. 17: 2723.
https://doi.org/10.3390/cancers17172723
APA Style
Lode, H. N., Holko, P., Wieczorek, A., Siebert, N., Valteau-Couanet, D., Garaventa, A., Cañete, A., Anderson, J., Yaniv, I., Ash, S., Gray, J., Luksch, R., Manzitti, C., Troschke-Meurer, S., Ebeling, T., Kawalec, P., Śladowska, K., & Ladenstein, R. L.
(2025). Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison. Cancers, 17(17), 2723.
https://doi.org/10.3390/cancers17172723
